We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Israel-based Teva Pharmaceutical Industries Limited (TEVA - Free Report) is a global pharmaceutical company with a strong presence in the generics as well as branded markets. Teva’s main branded products include Copaxone (multiple sclerosis) and Azilect (Parkinson’s disease). Besides this, Teva’s branded product portfolio consists of respiratory products like ProAir, a short-acting beta-agonist for the treatment of bronchial spasms and exercise-induced bronchospasm, and Qvar, an inhaled corticosteroid for long-term control of chronic bronchial asthma.
Moreover, the company has several candidates in its pipeline. Earlier this week, Teva completed its acquisition of Allergan’s generics business (Actavis Generics). The company also announced a deal to acquire Allergan’s Anda Inc., the 4th largest distributor of generic pharmaceuticals in the U.S., for $500 million. The Anda deal is slated to close in the second half of the year.
Teva’s earnings track record has been good with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 4.56%.
Currently, TEVA has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: TEVA’s second quarter earnings came in at $1.25 per share, beating consensus estimates of $1.18.
Revenues: Teva posted revenues of $5 billion, surpassing consensus estimates of $4.8 billion.
Key Stats: Currency fluctuations cut second quarter revenues by about $141 million. Lead branded product, Copaxone, posted worldwide sales of $1.1 billion, up 8%. Meanwhile, generic revenues declined during the quarter.
2016 Outlook: The company expects revenues of $22.0-22.5 billion and earnings of $5.20-5.40 per share in 2016. The Zacks Consensus Estimate for 2016 revenue and earnings are $22.29 billion and $5.16 per share and, respectively.
Check back later for our full write up on this TEVA earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Teva (TEVA) Beats on Q2 Earnings & Revenues
Israel-based Teva Pharmaceutical Industries Limited (TEVA - Free Report) is a global pharmaceutical company with a strong presence in the generics as well as branded markets. Teva’s main branded products include Copaxone (multiple sclerosis) and Azilect (Parkinson’s disease). Besides this, Teva’s branded product portfolio consists of respiratory products like ProAir, a short-acting beta-agonist for the treatment of bronchial spasms and exercise-induced bronchospasm, and Qvar, an inhaled corticosteroid for long-term control of chronic bronchial asthma.
Moreover, the company has several candidates in its pipeline. Earlier this week, Teva completed its acquisition of Allergan’s generics business (Actavis Generics). The company also announced a deal to acquire Allergan’s Anda Inc., the 4th largest distributor of generic pharmaceuticals in the U.S., for $500 million. The Anda deal is slated to close in the second half of the year.
Teva’s earnings track record has been good with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 4.56%.
Currently, TEVA has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: TEVA’s second quarter earnings came in at $1.25 per share, beating consensus estimates of $1.18.
Revenues: Teva posted revenues of $5 billion, surpassing consensus estimates of $4.8 billion.
Key Stats: Currency fluctuations cut second quarter revenues by about $141 million. Lead branded product, Copaxone, posted worldwide sales of $1.1 billion, up 8%. Meanwhile, generic revenues declined during the quarter.
2016 Outlook: The company expects revenues of $22.0-22.5 billion and earnings of $5.20-5.40 per share in 2016. The Zacks Consensus Estimate for 2016 revenue and earnings are $22.29 billion and $5.16 per share and, respectively.
TEVA PHARM ADR Price
TEVA PHARM ADR Price | TEVA PHARM ADR Quote
Check back later for our full write up on this TEVA earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>